ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial

Abstract

We demonstrate that the innovative strategy of combining MF with semi-selective IA may substantially increase IgM elimination and affect classical complement activation. Our findings suggest that this new treatment concept could be an efficient strategy for recipient desensitization in ABO- and HLA-incompatible transplantation.

ABO-Incompatible Kidney Transplantation

“…In contrast, unselective IA was less effective in the removal of anti-A/B antibodies of the IgM (74 versus 30%, P  < 0.001) and IgG3 subclass (72 versus 42%, P  < 0.05). The same group found that a combination of membrane separation and unselective IA effectively removed IgG and IgM antibodies and effector molecules such as complement C1q component (11). No significant differences were found in clinical studies that compared the impact of different IA strategies on clinical outcomes, including anti-A/B antibody reduction, survival, kidney function, rejection episodes, or complications (12).…”

Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti‐PLA2R positive primary membranous nephropathy

“…12,15,47,48 The system uses microprocessors to monitor all predetermined adsorption and desorption parameters of the adsorbers.…”

ABO‐incompatible liver transplantation: Is it a viable option with modern innovation?

“…The advent of extracorporeal therapies, including TPE, DFP, and antigen‐specific immunoadsorption, enable depletion of resident IHs, reducing the chance of AMR . DFP and immunoadsorption have been developed in an attempt to selectively deplete anti‐A and anti‐B IHs void of the disadvantages linked to TPE including hypersensitivity, citrate toxicity, and hemodynamic stress . Although implementation of DFP is largely confined to Japanese centers and immunoadsorption has yet to become broadly utilized in ABO‐ILT, both methods typify alternative options for IH titer reduction with minimized side effects .…”